Metraipolis › archive › dc_b36e41c8baf3

Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic… — Europe PMC PMID:41030254

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41030254
DOI
10.3389/fmed.2025.1638176
License (as archived)
solo-consultazione
Archived
2026-11-09T23:20:14.573Z
SHA-256 of the archived text
31ac51f21a3cee92caecdd1e89bb8fd100a7f941c4361d44c3c5ea3ed690665f
Stable URL of this page
https://metraipolis.com/documento/dc_b36e41c8baf3

How to cite

Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic… — Europe PMC PMID:41030254 — Europe PMC (en), https://europepmc.org/article/MED/41030254 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b36e41c8baf3 (Metraipolis archive dc_b36e41c8baf3, sha256 31ac51f21a3cee92caecdd1e89bb8fd100a7f941c4361d44c3c5ea3ed690665f)
BibTeX
@misc{dcb36e41c8baf3,
  title = {Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic… — Europe PMC PMID:41030254},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41030254},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b36e41c8baf3; sha256 31ac51f21a3cee92caecdd1e89bb8fd100a7f941c4361d44c3c5ea3ed690665f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41030254. Agents can read the archived copy with the MCP tool read_document.